GLP-1 Receptor Agonist Overview for Cardiometabolic Health

Discover the significance of cardiometabolic health GLP-1 receptor agonists in modern health approaches and diabetes management.

Abstract

In the complex landscape of chronic disease, the intersection of type 2 diabetes and heart failure presents a significant clinical challenge. These two conditions are deeply intertwined, sharing common pathophysiological pathways that involve chronic inflammation, metabolic dysfunction, and cardiovascular stress. This educational post explores this intricate relationship, drawing upon the latest findings from leading researchers to illuminate how we can bridge the gap in care. We will delve into the physiological mechanisms that link diabetes to heart failure, including the roles of hyperglycemia, insulin resistance, and the renin-angiotensin-aldosterone system (RAAS). A central focus will be on two groundbreaking classes of medications—SGLT2 inhibitors and GLP-1 receptor agonists—and their dual benefits in managing both glycemic control and cardiovascular health. We will summarize the evidence from pivotal clinical trials, including EMPEROR, DAPA-HF, and SELECT, that have reshaped our treatment guidelines. Furthermore, this post will detail how our multidisciplinary team at Injury Medical Clinic integrates these advanced medical strategies with holistic approaches like chiropractic care and functional medicine to provide comprehensive, patient-centered treatment for a range of cardiometabolic conditions, including type 1 diabetes, chronic kidney disease (CKD), and dyslipidemia.

Our Integrative Team: A Collaborative Model of Care

At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas, our philosophy is rooted in a collaborative, integrative approach. My extensive training as a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), and board-certified Family Nurse Practitioner (FNP-BC), combined with certifications in functional and lifestyle medicine, allows me to view patient health through a multifaceted lens. This perspective is crucial, especially when managing complex, intertwined conditions like diabetes and heart failure.

Our collaboration fortifies this comprehensive model with Dr. Maria Guadalupe Cardenas, MD, who serves as our esteemed Medical Director and Collaborative Physician. With over 40 years of experience as a board-certified internist (Texas MD License #J2933, NPI #1164426749), Dr. Cardenas provides invaluable medical oversight and works alongside our team. This multidisciplinary setup, where a medical doctor provides medical direction alongside a chiropractor leading a team of diverse health professionals, is a cornerstone of modern integrative and injury care. Together, our team integrates:

• Medical Oversight (Dr. Cardenas): Ensuring all treatment plans are medically sound; managing complex conditions such as diabetes, cardiology, and nephrology; and prescribing advanced medications, including SGLT2 inhibitors and GLP-1 agonists, when clinically indicated.
• Chiropractic and Functional Medicine (Dr. Jimenez): Addressing musculoskeletal imbalances, improving nervous system function, and using functional medicine to identify and correct underlying metabolic and inflammatory drivers of disease.
• Comprehensive Services: Our clinic provides personal injury care, advanced rehabilitation, nutritional counseling, and lifestyle modification programs to support a patient’s complete health journey.

This integrated system ensures that whether a patient is recovering from an injury or managing a chronic condition like heart disease, they receive a holistic treatment plan that targets their symptoms and the root cause of their illness, promoting true, long-lasting wellness.

Understanding the Pathophysiological Link Between Diabetes and Heart Failure

As a clinician who has seen the devastating overlap of these conditions firsthand, I believe it’s essential to start with the “why.” Understanding the underlying physiology is the key to appreciating why certain treatments work and why a multi-pronged approach is necessary. Diabetes and heart failure are not just two separate diseases that happen to coexist; they are, as my colleagues in the field often say, “joined at the hip.”

Type 2 diabetes is an independent and powerful risk factor for developing heart failure. This risk exists even without the presence of traditional atherosclerotic cardiovascular disease, leading to a condition known as diabetic cardiomyopathy. The journey begins with a cascade of metabolic dysregulation:

1. Hyperglycemia: Chronically elevated blood sugar levels.
2. Insulin Resistance: The body’s cells become less responsive to insulin, a hormone essential for glucose uptake.
3. Hyperinsulinemia: To compensate for this resistance, the pancreas’s beta cells work overtime, flooding the body with excess insulin.

This metabolic milieu creates a perfect storm for cardiovascular damage. The state of hyperinsulinemia, along with the increased fat tissue (adiposity) common in type 2 diabetes, fuels a state of chronic, low-grade inflammation. This inflammation is a primary driver of several damaging processes:

• Endothelial Dysfunction: The endothelium, the delicate inner lining of our blood vessels, becomes inflamed and dysfunctional. This is a critical first step in the formation of atherosclerotic plaques, which can narrow and harden arteries.
• Dyslipidemia: By definition, individuals with diabetes often have unhealthy lipid profiles (high triglycerides, low HDL cholesterol), further contributing to plaque buildup.
• Activation of the Renin-Angiotensin-Aldosterone System (RAAS): This hormonal system, which regulates blood pressure and fluid balance, becomes overactive, leading to vasoconstriction, fluid retention, and increased cardiac strain.
• Myocardial Fibrosis and Hypertrophy: The heart muscle itself begins to change. It becomes stiff (fibrosis) and thickens (left ventricular hypertrophy or LVH) in an attempt to pump blood against higher pressures and increased resistance.

Together, these pathways lead directly to the structural and functional changes that define heart failure. The development of coronary artery disease can lead to ischemic cardiomyopathy, while the direct effects of metabolic dysfunction on the heart muscle lead to diabetic cardiomyopathy.

The Two Faces of Heart Failure: HFrEF vs. HFpEF

When we discuss heart failure, it is crucial to classify it by ejection fraction (EF), the percentage of blood the left ventricle pumps with each contraction. This classification dictates our treatment approach.

Heart Failure with Preserved Ejection Fraction (HFpEF)

• Definition: Characterized by an EF of 50% or greater.
• The Problem: The primary issue here is diastolic dysfunction. The heart muscle is stiff and cannot relax properly to fill with blood between beats.
• Physiology: This is often associated with concentric remodeling, in which the heart’s walls thicken uniformly, reducing the chamber volume. It is driven by systemic inflammation, microvascular dysfunction in the coronary arteries, and interstitial fibrosis.
• Patient Profile: HFpEF is more common in older adults, women, and individuals with obesity, diabetes, and hypertension.
• Treatment Focus: The main goals are decongestion (relieving fluid overload), managing risk factors like blood pressure and diabetes, and, as we’ll discuss, using SGLT2 inhibitors to address the underlying remodeling.

Heart Failure with Reduced Ejection Fraction (HFrEF)

• Definition: Characterized by an EF of less than 40%.
• The Problem: The issue shifts from impaired relaxation to impaired contractility. The heart muscle is weak and cannot pump blood effectively.
• Physiology: This is often associated with eccentric remodeling, in which the ventricle dilates. It is driven by significant neurohormonal activation, particularly the overactivation of the RAAS and the sympathetic nervous system.
• Patient Profile: HFrEF is more common in men and is frequently caused by ischemic heart disease (e.g., prior heart attacks).
• Treatment Focus: The cornerstone of HFrEF management is “quadruple medical therapy” to counteract the harmful neurohormonal activation.

The Four Pillars of Modern Cardiometabolic Management

Just as HFrEF management relies on four pillars of therapy (ARNIs, beta-blockers, MRAs, and SGLT2 inhibitors), the American Diabetes Association now advocates for a four-pillared approach to reducing cardiovascular risk in patients with diabetes:

1. Glycemic Management: Controlling blood sugar levels.
2. Blood Pressure Management: Achieving and maintaining a healthy blood pressure.
3. Lipid Management: Optimizing cholesterol and triglyceride levels.
4. Cardiorenal Benefit Agents: Medications proven to protect the heart and kidneys, independent of their glucose-lowering effects.

This fourth pillar represents a paradigm shift in our thinking. We are no longer just treating a number (A1c); we are actively protecting vital organs. This is where SGLT2 inhibitors and GLP-1 receptor agonists have become indispensable tools.

The Rise of SGLT2 Inhibitors: A Game-Changer for Heart and Kidneys

The journey of Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors is a fascinating one. When this class of drugs first emerged around 2014 with canagliflozin, we saw it as a novel way to manage diabetes by causing the kidneys to excrete excess glucose in the urine. It was an interesting mechanism, but few of us foresaw the revolutionary impact these drugs would have on both cardiology and nephrology.

Today, SGLT2 inhibitors are a core pillar of heart failure therapy, recommended for patients with or without diabetes. This recommendation is built on a mountain of evidence from landmark clinical trials.

Pivotal Trials Demonstrating Cardiorenal Protection

• DAPA-HF and EMPEROR-Reduced: These two trials, using dapagliflozin and empagliflozin respectively, were groundbreaking. They showed that in patients with HFrEF (with or without diabetes), SGLT2 inhibitors significantly reduced the risk of cardiovascular death and hospitalization for heart failure by approximately 25-26%. These results cemented their place in guideline-directed medical therapy.
• EMPEROR-Preserved: This trial broke the “curse” of HFpEF. For decades, no therapy had shown a clear benefit in this population. EMPEROR-Preserved demonstrated that empagliflozin could reduce the risk of hospitalization for heart failure in patients with preserved ejection fraction, a monumental achievement for a notoriously difficult-to-treat condition.
• EMPA-KIDNEY, CREDENCE, and SCORED: These trials (using empagliflozin, canagliflozin, and sotagliflozin) collectively showed that SGLT2 inhibitors are also powerfully protective of the kidneys. They were shown to reduce the risk of CKD progression, the need for dialysis, or death from kidney disease by up to 38%. This is critically important, as kidney disease is a common and deadly comorbidity in both diabetes and heart failure.

Based on this evidence, we can now initiate SGLT2 inhibitors in patients with a glomerular filtration rate (GFR) as low as 20 mL/min and continue them even as a patient approaches or begins dialysis.

How SGLT2 Inhibitors Work Their Magic: More Than Just Glucose Lowering

The profound benefits of SGLT2 inhibitors extend far beyond simply lowering blood sugar. They induce a complex array of physiological changes that directly protect the heart and kidneys. They work by blocking the SGLT2 protein in the proximal convoluted tubule of the kidney, thereby preventing the reabsorption of glucose and sodium into the bloodstream. This leads to a cascade of favorable effects.

What SGLT2 Inhibitors Increase:

• Natriuresis: The excretion of sodium (and water) in the urine. This acts as a gentle diuretic, reducing fluid overload and preload on the heart.
• Myocardial Glucose Availability: While seemingly counterintuitive, the metabolic shift they cause can improve the heart’s energy efficiency.
• Plaque Stability: They promote the stability of existing atherosclerotic plaques, reducing the likelihood of rupture and heart attack.
• Ketosis: one of the most exciting mechanisms. SGLT2 inhibitors promote a mild state of ketosis. A sick, failing heart struggles to use glucose for energy. However, it remains highly efficient at using ketone bodies as fuel. By providing this preferred fuel source, SGLT2 inhibitors literally help energize the failing heart muscle.

What SGLT2 Inhibitors Decrease:

• Metabolic Demand on the Heart: By improving efficiency and reducing workload, they lower the heart’s overall energy and oxygen demand.
• Glomerular Pressure: By reducing reabsorption in the proximal tubule, they lower the pressure within the kidney’s filtering units (the glomeruli), thereby slowing the progression of kidney disease. This is achieved via tubuloglomerular feedback, in which increased sodium delivery to the macula densa triggers afferent arteriolar vasoconstriction, thereby lowering intraglomerular pressure.
• Myocardial Fibrosis and Inflammation: They directly reduce the inflammation and stiffening of the heart muscle, which is particularly beneficial in HFpEF.
• Oxidative Stress: They have a global effect on reducing damaging oxidative stress throughout the body.
• Epicardial Adipose Tissue: One of the key drivers of inflammation in diabetic heart disease is the fat tissue that sits directly on the heart’s surface. SGLT2 inhibitors have been shown to reduce this specific, highly inflammatory fat depot, directly blunting a primary source of cardiovascular inflammation.

From a chiropractic and functional medicine perspective, these mechanisms are incredibly compelling. They align perfectly with our goal of reducing systemic inflammation, optimizing cellular energy production (mitochondrial function), and restoring metabolic balance. While the medication provides a powerful push, we support these pathways through dietary recommendations (like a modified ketogenic or low-glycemic diet), targeted nutritional supplementation, and lifestyle changes that further reduce inflammation and oxidative stress. This integrated approach creates a synergistic effect, enhancing the medication’s benefits and promoting deeper healing.

GLP-1 Receptor Agonists: A Multifaceted Approach to Cardiometabolic Health

While SGLT2 inhibitors are a go-to for heart failure, another class of drugs, Glucagon-Like Peptide-1 (GLP-1) receptor agonists, are favored for patients with established atherosclerotic cardiovascular disease (ASCVD). Drugs like semaglutide (Ozempic, Rybelsus, Wegovy) and liraglutide (Victoza) have reshaped how we treat obesity and protect the cardiovascular system. These medications mimic the action of the natural incretin hormone GLP-1, which is released from the gut after eating. This leads to a cascade of beneficial effects.

The Power of GLP-1 Agonists:

• Delayed Gastric Emptying and Increased Satiety: GLP-1 agonists slow the rate at which food leaves the stomach. This not only helps lower the spike in blood sugar after meals (postprandial glucose excursions) but also makes patients feel full sooner and for longer, promoting significant weight loss.
• Reduced Inflammation and Endothelial Dysfunction: Chronic, low-grade inflammation is a key driver of atherosclerosis. GLP-1 agonists have been shown to lower inflammatory markers and improve endothelial function (the inner lining of blood vessels), helping stabilize atherosclerotic plaques and prevent rupture.
• Glucose-Dependent Action: A major safety advantage of these drugs is that they only stimulate insulin release when blood glucose is high. This “smart” mechanism means they carry a very low risk of causing hypoglycemia (low blood sugar), making them safe for patients to use without fear of their sugar dropping dangerously, especially overnight.

Groundbreaking Clinical Trial Evidence

The journey of GLP-1 agonists is a perfect example of how science can deliver unexpected triumphs. Around 2008, the FDA mandated that all new diabetes drugs undergo large-scale cardiovascular outcomes trials, primarily to prove they weren’t harmful. What researchers discovered was shocking in the best way possible.

• The LEADER Trial (2016): This study on liraglutide (Victoza) involved over 9,000 high-risk patients. Not only was the drug safe, but it also delivered a 13% reduction in major adverse cardiovascular events (MACE)—a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke.
• SUSTAIN-6 and PIONEER-6 Trials: These trials, which studied injectable and oral semaglutide, respectively, showed even more impressive results, with risk reductions in MACE reaching as high as 26%.
• The SELECT Trial: a game-changer. It studied semaglutide (at the 2.4 mg Wegovy dose) in over 17,000 overweight or obese patients. The results were stunning: a 20% reduction in MACE. This trial firmly established GLP-1 agonists as cardiovascular risk-reduction drugs, independent of their glucose-lowering effects. It also highlighted a particularly strong signal for reducing non-fatal stroke, a benefit we had not seen with other drug classes.

From a functional medicine perspective, these findings are thrilling. The significant weight loss—often 15% or more of body weight—achieved with these drugs directly targets visceral obesity. This metabolically active fat surrounds our organs and churns out inflammatory cytokines like IL-6 and TNF-alpha. By reducing this fat, we are directly turning down the dial on systemic inflammation.

SGLT2 Inhibitors and GLP-1 Agonists in Type 1 Diabetes: Off-Label Considerations

While SGLT2 inhibitors and GLP-1 receptor agonists are not FDA-approved for type 1 diabetes in the US, their powerful cardiometabolic benefits have led to careful, off-label consideration in selected patients. For an individual with long-standing type 1 diabetes (like LADA), obesity, and high cardiovascular and renal risk, the potential benefits can be substantial. This is an area where medical direction from Dr. Cardenas is paramount.

For SGLT2 inhibitors, the key benefits in a type 1 patient would be the proven reductions in heart failure hospitalizations and CKD progression. However, this must be balanced with the increased risk of euglycemic diabetic ketoacidosis (DKA). Rigorous patient education is essential, including:

• Sick-Day Rules: Instructing patients to hold the SGLT2 inhibitor during acute illness, dehydration, or fasting.
• Ketone Monitoring: Providing urine ketone strips and clear action plans if ketones become elevated.
• Insulin Management: Emphasizing the need to continue basal insulin, even if oral intake is poor.

Similarly, GLP-1 agonists can be considered off-label for their profound weight loss effects, which can improve insulin sensitivity and reduce overall cardiometabolic strain. We navigate insurance barriers by using labeled indications, such as obesity, where appropriate. The titration must be slow to manage gastrointestinal side effects. In our clinic, such decisions are made collaboratively, with extensive patient counseling and safety protocols in place.

---

Optimizing Your Wellness- Video

---

Integrating Chiropractic Care into Cardiometabolic Management

You might wonder how chiropractic care fits into this complex picture of pharmacology and internal medicine. The connection is deeper than it may first appear and is a cornerstone of our integrative model.

• Musculoskeletal Optimization: Chronic conditions like heart failure and diabetes take a toll on the body. Pain from spinal and pelvic misalignments can be a significant barrier to physical activity, which is essential for improving insulin sensitivity and cardiac conditioning. By performing chiropractic adjustments, we reduce mechanical pain, enabling patients to adhere to exercise and rehabilitation programs.
• Autonomic Modulation: The nervous system regulates heart rate, blood pressure, and inflammatory responses. Chiropractic care, through gentle spinal mobilization and targeted breathing techniques, can help improve heart rate variability and vagal tone. By reducing stress on the nervous system, we lower the catecholamine burden, which benefits blood pressure, glucose control, and overall cardiovascular health.
• Rehabilitation Synergy: As a chiropractor with a deep background in rehabilitation, I work to ensure patients can move safely and effectively. We coordinate with cardiac rehab programs to create joint-sparing exercise plans. For instance, optimizing thoracic cage mobility can support respiratory mechanics, which is crucial for patients with heart failure or coexisting obstructive sleep apnea (OSA). This condition dramatically worsens cardiometabolic outcomes.

My clinical observations, documented on platforms like WellnessDoctorRx and in my professional updates, consistently show that patients receiving this integrated care report better pain control, improved ability to exercise, and higher-quality sleep. These functional gains translate into more stable glucose profiles and better blood pressure control at follow-up visits, creating a powerful synergy with the medical therapies prescribed by Dr. Cardenas.

Putting It All Together: A Clinical Case Study

Let’s consider a common patient scenario to illustrate how we apply these principles.

Patient: “Bob,” a recently insured man with type 2 diabetes, was admitted for a heart attack two months ago. He received a stent and now has heart failure with reduced ejection fraction (HFrEF). His current medications are a sulfonylurea, a DPP-4 inhibitor, and metformin—a common, low-cost regimen for an uninsured patient. His A1C is 7.0%.

The Challenge: Bob’s A1C is at target, but his medication regimen does nothing to address his new, life-threatening cardiovascular diagnoses. In fact, sulfonylureas can increase the risk of hypoglycemia, especially in older adults, and have been linked to poor cardiovascular outcomes. DPP-4 inhibitors are expensive and offer no cardiac benefit. How do we transition him to a regimen that will save his life?

Our Integrated Treatment Strategy:

1. Prioritize Safety and Cardiovascular Benefit: The primary goal is no longer just lowering glucose; it is to reduce his risk of another heart attack and manage his heart failure.
2. Deprescribe Inappropriate Medications:

• • Stop the Sulfonylurea: This is the first and most critical step. The risk of hypoglycemia is significant, and the drug offers no cardiovascular protection.
  • Stop the DPP-4 Inhibitor: This medication is essentially a much weaker, less effective, and more expensive version of a GLP-1 agonist. It provides no weight loss or a proven reduction in MACCE.

• Initiate Guideline-Directed Medical Therapy:

• • Start an SGLT2 Inhibitor: Given his diagnosis of HFrEF, Bob is a perfect candidate for an SGLT2 inhibitor, such as dapagliflozin or empagliflozin. This is non-negotiable for improving his heart failure outcomes.
  • Start a GLP-1 Receptor Agonist: Because he has established ASCVD (evidenced by his heart attack and stent), a GLP-1 agonist is strongly indicated to reduce his risk of future events.
  • Continue Metformin: Metformin remains a safe, effective drug that reduces hepatic gluconeogenesis (sugar production by the liver). It can be combined with an SGLT2 inhibitor in a single pill (e.g., Synjardy or Xigduo XR) to reduce pill burden.

• Embrace Good” Polypharmacy: As a cardiology NP would emphasize, this is a case where polypharmacy is not only necessary but life-saving. In addition to the diabetes medication changes, Bob must also be started on the four pillars of HFrEF therapy: an ARNI (or ACEi/ARB), a beta-blocker, and an MRA. We must get comfortable with complex regimens when treating complex diseases.
• Integrate Chiropractic and Lifestyle Care:

• • Chiropractic Adjustments: We would implement a care plan to address any spinal misalignments that could be impairing autonomic nervous system function. By optimizing nerve flow, we can help support better heart rate variability and blood pressure regulation.
  • Functional Nutrition: We would design an anti-inflammatory, low-glycemic meal plan to support weight loss, reduce metabolic stress, and enhance the effects of the new medications.
  • Rehabilitation: A supervised exercise program is crucial for cardiac rehab. Our team would guide Bob through a safe and effective plan to improve his exercise tolerance and overall physical function, as measured in trials like the STEP-HFpEF study.

This comprehensive, team-based approach, led by the combined expertise of Dr. Cardenas and myself, ensures that Bob receives the most advanced medical care while also addressing the foundational pillars of his health. This is the future of managing cardiometabolic disease, and it is the standard of care we provide every day at Injury Medical Clinic.

References

• American Diabetes Association. (2024). Standards of Medical Care in Diabetes—2024. Diabetes Care.
• Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., … & EMPEROR-Preserved Trial Investigators. (2021). Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 385(16), 1451–1461.
• Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., … & SCORED trial investigators. (2021). Sotagliflozin in patients with diabetes and recent worsening heart failure. New England Journal of Medicine, 384(2), 117–128.
• Butler, J., et al. (2022). DELIVER (Dapagliflozin in HFmrEF/HFpEF). New England Journal of Medicine.
• Eckel, R. H., et al. (2014). 2013 AHA/ACC Guideline on Lifestyle Management. Circulation.
• Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., … & Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation, 139(25), e1082-e1143.
• Heerspink, H. J. L., et al. (2020). DAPA-CKD Trial. New England Journal of Medicine.
• Hernandez, A. F., Green, J. B., Janmohamed, S., D’Agostino, R. B., Granger, C. B., Jones, N. P., … & Buse, J. B. (2018). Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomized placebo-controlled trial. The Lancet, 392(10157), 1519-1529.
• Jimenez, A. Professional Profile.
• Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Christensen, L., Davies, M., … & Petrie, M. C. (2023). Semaglutide in patients with heart failure with preserved ejection fraction and obesity. New England Journal of Medicine, 389(12), 1069-1084.
• Lavie, C. J., et al. (2019). Exercise and Cardiometabolic Health. Mayo Clinic Proceedings.
• Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., … & Wiklund, O. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 41(1), 111-188.
• Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., … & Buse, J. B. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311–322.
• McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., … & Desai, A. S. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995-2008.
• Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., … & EMPEROR-Reduced Trial Investigators. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine, 383(15), 1413–1424.
• Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. L., Charytan, D. M., … & CREDENCE Trial Investigators. (2019). Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England Journal of Medicine, 380(24), 2295–2306.
• Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hood, K. (2015). Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care, 38(9), 1687-1693.
• Ryan, D. H., Lingvay, I., Colhoun, H. M., Deanfield, J., Emerson, S. S., Kahn, S. E., … & Marso, S. P. (2023). Semaglutide effects on cardiovascular outcomes in people with overweight or obesity. New England Journal of Medicine.
• The EMPA-KIDNEY Collaborative Group. (2023). Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 388(2), 117-127.
• S. Food & Drug Administration. (2021). Wegovy Label.
• WellnessDoctorRx Clinical Observations.

SEO Tags: heart failure, type 2 diabetes, SGLT2 inhibitors, GLP-1 receptor agonists, integrative chiropractic care, Dr. Alex Jimenez, El Paso TX, functional medicine, diabetic cardiomyopathy, HFpEF, HFrEF, cardiorenal protection, empagliflozin, dapagliflozin, canagliflozin, cardiovascular disease, chronic kidney disease, inflammation, metabolic health, Dr. Maria Cardenas, obesity, semaglutide, atherosclerosis, weight loss, diabetes care, MACE reduction, stroke prevention, LADA, type 1 diabetes, dyslipidemia, euglycemic DKA, sick day rules, OSA, cardiac rehab, internal medicine oversight, El Paso Injury Medical Clinic, Mission Plaza Injury Medical Clinic